Weeks, Not Years: How Oxford's Bundibugyo Vaccine Could Reach East Africa Before the Outbreak Does

In a laboratory on the southern edge of Oxford, a chimpanzee cold virus is being reprogrammed. Researchers have stripped out the genetic instructions that once told it to make a chunk of the Covid spike protein, and slipped in a different cargo: a small string of code from the Bundibugyo strain of Ebola virus, named for the western Ugandan district where it first leapt into people in 2007. If everything holds, the shot will be ready for human trials in two to three months. For a continent that watched the Bundibugyo strain go quiet for more than a decade and then return last month with hundreds of suspected cases and dozens of confirmed deaths, that timeline is the entire story.

The Oxford Vaccine Group, the same team that built the AstraZeneca Covid jab, confirmed this week that animal testing of its Bundibugyo candidate is already under way in the city. Professor Teresa Lambe, the group's Calleva Head of Vaccine Immunology and one of the lead scientists behind the AstraZeneca dose, told the BBC the team was preparing for the worst case scenario, adding that even if contact tracing and quarantine held the current outbreak, they could not afford to slow down. The Serum Institute of India, the world's largest vaccine producer by volume, is on standby in Pune to manufacture clinical-grade doses the moment Oxford ships starting material. Lambe described the Indian partner as ready to move quickly and at scale once the laboratory hands over the raw material.

For the Kenyan diaspora — particularly the tens of thousands of Kenyan-born nurses, care workers and laboratory scientists scattered across NHS trusts in England, Scotland and Wales — the announcement landed on a tense week. The World Health Organization on Sunday declared the central African outbreak a public health emergency of international concern and upgraded the DRC's national risk profile from high to very high. Regional risk, which directly touches Kenya through its long western border with Uganda and its busy lorry routes through the Malaba and Busia crossings, was raised to high. International risk, for now, remains low. The framing matters: Bundibugyo Ebola has not yet slipped into long-distance air travel, but it has done so before, and Kenyan families are paying close attention to the new vaccine because they know what a contained outbreak can become if a single border case slips through.

A virus named after a Ugandan district

Bundibugyo Ebola is the rarest of the three Ebola species capable of causing large human outbreaks, and the only one for which no proven vaccine currently exists. It was first identified in 2007 during an outbreak in Uganda's Bundibugyo district, an isolated stretch of country in the western Rift below the Rwenzori mountains. A second outbreak emerged in north-eastern Democratic Republic of Congo in 2012, and then the strain disappeared from human surveillance for more than a decade. Its return this month — initially in a cluster of cases in DR Congo with a spillover into Uganda — surprised epidemiologists. The strain kills roughly one in three of the people it infects, lower than the notorious Zaire Ebola ceiling but devastating in any community that lacks intensive care.

Existing Ebola vaccines, including the Merck-made Ervebo shot deployed during the 2018 to 2020 outbreaks in eastern DR Congo, were built against the Zaire species. Cross-protection against Bundibugyo is unproven. A separate Bundibugyo candidate has been moving through earlier-stage development at another laboratory, but doses for that one would take six to nine months to ready for testing. Oxford's two-to-three-month figure, if it survives animal data, would be the shortest path the world has to a tool that works against the species now circulating.

The Covid jab, rewired

The reason Oxford can move this fast is the platform itself. ChAdOx1 — the modified chimpanzee adenovirus that underpinned the AstraZeneca Covid jab — was always designed as a delivery truck rather than a single product. The virus is genetically blunted so that it cannot replicate in human cells; what it can do is shuttle a short genetic payload into the body, where the cell reads the instructions and briefly produces a fragment of whatever pathogen the scientists targeted. The immune system, recognising the fragment as foreign, learns to make antibodies that will later attack the real virus. Swap the payload and you have, in principle, a new vaccine.

The Oxford team had already been engineering ChAdOx1 versions against the Sudan species of Ebola and against the related Marburg virus, work that started after the West African epidemic of 2014. Loading Bundibugyo genetic material was therefore not a leap into the unknown but the next step along an existing road. The WHO cautioned this week that no animal data yet supports the new vaccine's effectiveness against Bundibugyo, and a spokesperson said the path to clinical trials remained dependent on those animal study results. It is a deliberate caution: a candidate that works in cells in a dish does not always protect a living organism.

Why the diaspora is watching

In Kenyan diaspora WhatsApp groups across London, Birmingham, Reading and Manchester this weekend, the Oxford announcement circulated alongside a quieter line of conversation: who back home lives near the Uganda border, who is travelling for an upcoming wedding in Kakamega or a funeral in Bungoma, and which hospitals would be the first to admit a suspected case. The Kenyan Ministry of Health has not raised travel restrictions, but it has reactivated screening at Busia and Malaba and reminded clinicians to flag any haemorrhagic fever consistent with viral haemorrhagic disease.

There is a second, professional layer to the diaspora interest. Kenyan-trained nurses are now an entrenched part of the British care workforce, and most of them know — because they lived through the 2014 West Africa epidemic — what frontline Ebola response looks like. A vaccine that works against Bundibugyo would be deployed using ring vaccination, the method used in West Africa, in which only those at highest risk are immunised: close contacts of confirmed cases, contacts of those contacts, and health workers treating the sick. Several of the people most likely to wear those doses first will be East African nationals working in DRC, Uganda and Kenya. Several more will be diaspora professionals who fly home to help.

The £20 million and the politics of speed

The British government this week announced up to twenty million pounds in funding to support frontline workers, infection control and surveillance in DR Congo and Uganda. The package is modest in pandemic-funding terms but unusually fast in disbursement, and a portion of it is expected to flow to East African research institutions through partnerships that the Africa Centres for Disease Control has been building with Wellcome and the Coalition for Epidemic Preparedness Innovations. For Nairobi-based KEMRI and Kenya's Centre for Virus Research, both of which have long-standing collaborations with Oxford and the London School of Hygiene and Tropical Medicine, the funding may help underwrite a Kenya-side arm of any eventual clinical trial.

Whether any of this is enough depends, in the end, on epidemiology. The Bundibugyo cluster has not yet shown the explosive transmission of Zaire Ebola, but the WHO's Abdirahman Mahamud, director of health emergency response operations, warned this week that the strain's potential to spread had become high enough to change the whole dynamic. A vaccine ready in eight to twelve weeks would arrive after the current peak, not before it. Its real value is for the next outbreak — and, if Bundibugyo keeps reappearing on a thirteen-year cycle, the one after that. For the diaspora, that long horizon is itself the point. Families abroad do not just want news of the current emergency; they want the next one to be less frightening than this one.